C4 Therapeutics, Inc. (CCCC) Stock Price & Analysis
C4 Therapeutics, Inc. (CCCC) fell 6.85% to USD 3.4 as of July 25, 2026 at 03:02 UTC, according to Nexqual real-time market data.
CCCC last closed at USD 3.65; the session ranged USD 3.39–3.68 on volume of 2,464,322 shares. Market capitalization is $375.93M, with a 52-week range of USD 1.69–5.17 (NMS). Source: Nexqual, July 25, 2026 at 03:02 UTC.
Key Statistics (as of July 25, 2026 at 03:02 UTC)
| Price | USD 3.4 |
|---|---|
| Change | ▼ 6.85% (down) |
| Previous Close | USD 3.65 |
| Open | USD 3.67 |
| Day Range | USD 3.39 – 3.68 |
| 52-Week Range | USD 1.69 – 5.17 |
| Volume | 2,464,322 shares |
| Market Cap | $375.93M |
| Exchange | NMS |
Technical Analysis (CCCC)
Nexqual's technical model rates CCCC "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 03:02 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 37.34 (neutral) |
| vs SMA50 | Below (USD 3.9) |
| MACD | -0.11 (negative) |
Analyst Ratings (CCCC)
Wall Street analysts rate CCCC "None" based on 6 analysts, with a mean price target of USD 13.33 (range USD 7–30), per Nexqual as of July 25, 2026 at 03:02 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 13.33 |
| High Target | USD 30 |
| Low Target | USD 7 |
| Buy / Hold / Sell | 7 / 0 / 0 |
Earnings (CCCC)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -0.23 |
| Revenue Estimate | $4.00M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.2 vs est -0.26 ▲ beat |
| 2025-12-31 | USD -0.18 vs est -0.39 ▲ beat |
| 2025-09-30 | USD -0.3 vs est -0.39 ▲ beat |
| 2025-06-30 | USD -0.37 vs est -0.38 ▲ beat |
Source: Nexqual, July 25, 2026 at 03:02 UTC.
Financials & Fundamentals (CCCC)
| Total Revenue | $34.86M |
|---|---|
| Revenue Growth (YoY) | -15.00% |
| Gross Margin | +78.34% |
| Operating Margin | -451.64% |
| Profit Margin | -297.76% |
| ROE | -48.35% |
| Debt / Equity | 24.95 |
| Current Ratio | 9.01 |
| Total Cash | $235.67M |
| Total Debt | $58.45M |
| Free Cash Flow | $-53.37M |
Source: Nexqual, July 25, 2026 at 03:02 UTC.
Financial Health Score (CCCC)
Nexqual rates C4 Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 03:02 UTC.
| Growth | Mixed — Revenue +1.0% YoY (annual), slow |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $236M cash vs $58M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$53M, burning cash |
| Efficiency | Critical — ROE -48%, ROA -19.9% |
Ownership (CCCC)
| Insider Ownership | +0.93% |
|---|---|
| Institutional Ownership | +86.90% |
| Shares Outstanding | 110.57M |
| Float | 83.71M |
| Short % of Float | +22.76% |
Source: Nexqual, July 25, 2026 at 03:02 UTC.
Leadership (CCCC)
C4 Therapeutics, Inc. is led by Andrew J. Hirsch (age 54), CEO, President & Director, per Nexqual as of July 25, 2026 at 03:02 UTC.
| CEO, President & Director | Andrew J. Hirsch (age 54) |
|---|---|
| Co-Founder, Independent Director & Member of Scientific Advisory Board | Kenneth C. Anderson (age 74) |
| Principal Accounting Officer, CFO, Head of Corporate Affairs & Treasurer | Kendra R. Adams (age 48) |
Major Backers & Investors (CCCC)
Notable institutional backers of C4 Therapeutics, Inc. include Morgan Stanley, RA Capital Management, L.P., Bain Capital Life Sciences Investors, LLC, according to Nexqual as of July 25, 2026 at 03:02 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Morgan Stanley | 8.21% |
| RA Capital Management, L.P. | 7.24% |
| Bain Capital Life Sciences Investors, LLC | 6.49% |
| Lynx1 Capital Management Lp | 6.33% |
| Soleus Capital Management, L.P. | 3.44% |
| Wasatch Advisors LP | 3.19% |
| JPMorgan | 2.92% |
| Two Sigma Investments, LP | 2.75% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 6.91% |
Source: Nexqual, July 25, 2026 at 03:02 UTC.
From C4 Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Our approach provides an opportunity to streamline clinical decision-making via a focused early clinical proof-of-concept, including early validation based on pharmacodynamic markers in healthy subjects, followed by potentially significant opportunities for expansion to several diseases. 5 Table of Contents Our TORPEDO Platform Our proprietary TORPEDO platform is an important element of our leading approach to TPD.
- Leveraging our proprietary TORPEDO platform, we efficiently design and optimize small molecule protein degraders that are highly active against their desired targets by harnessing the body's natural process for destroying unwanted proteins.
- We currently are advancing two clinical programs that were developed from our proprietary TORPEDO platform and have the potential to improve patients' outcomes. ◦ Develop cemsidomide as a potential best-in-class IKZF1/3 degrader: The Phase 1 trial of cemsidomide in combination with dexamethasone demonstrated a differentiated safety profile with compelling anti-myeloma activity.
- Under the Roche Agreement, we agreed to collaborate with Roche in the research, development, manufacture, and commercialization of target-binding degrader medicines using our proprietary TORPEDO platform for the treatment of cancers and other indications.
Partnerships
- In addition, as part of the collaboration, we have agreed to make milestone payments to Betta Pharma of up to $40.0 million following our receipt of approval of a New Drug Application for CFT8919 from the FDA, with the milestone amount based on the percentage of patients in contemplated clinical trials that were enrolled by Betta Pharma and the line of therapy of the approval.
- Clinical Trials of CFT8919 in Non-Small Cell Lung Cancer In May 2023, we entered into an exclusive licensing and collaboration agreement with Betta Pharma for the development and commercialization of CFT8919 in Greater China, including mainland China, Hong Kong SAR, Macau SAR and Taiwan.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| STTK | Shattuck Labs, Inc. | USD 7.43 | ▲ 5.84% |
| KYMR | Kymera Therapeutics, Inc. | USD 110.57 | ▲ 0.21% |
| NRIX | Nurix Therapeutics, Inc. | USD 23.38 | ▼ 0.93% |
| PRLD | Prelude Therapeutics Incorporat | USD 3.83 | ▼ 2.42% |
| FHTX | Foghorn Therapeutics Inc. | USD 4.85 | ▼ 6.91% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:02 UTC. This page is informational and not investment advice.